0001209191-17-067392.txt : 20171227 0001209191-17-067392.hdr.sgml : 20171227 20171227140702 ACCESSION NUMBER: 0001209191-17-067392 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171222 FILED AS OF DATE: 20171227 DATE AS OF CHANGE: 20171227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shames Richard S. CENTRAL INDEX KEY: 0001675878 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37852 FILM NUMBER: 171275898 MAIL ADDRESS: STREET 1: C/O PROTAGONIST THERAPEUTICS, INC. STREET 2: 521 COTTONWOOD DRIVE, SUITE 100 CITY: MILPITAS STATE: CA ZIP: 95035 FORMER NAME: FORMER CONFORMED NAME: Shame Richard S DATE OF NAME CHANGE: 20160527 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc CENTRAL INDEX KEY: 0001377121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980505495 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 BUSINESS PHONE: (510) 474-0170 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Therapeutics Inc DATE OF NAME CHANGE: 20130605 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Inc DATE OF NAME CHANGE: 20061002 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-12-22 0 0001377121 Protagonist Therapeutics, Inc PTGX 0001675878 Shames Richard S. C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BOULEVARD, SUITE 140 NEWARK CA 94560 0 1 0 0 Chief Medical Officer Common Stock 2017-12-22 4 M 0 3529 4.21 A 3529 D Common Stock 2017-12-22 4 S 0 3529 20.50 D 0 D Stock Option (right to buy) 4.21 2017-12-22 4 M 0 3529 0.00 D 2026-04-29 Common Stock 3529 33273 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 9, 2017. The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. /s/ Thomas P. O'Neil, Attorney-in-Fact 2017-12-26